Hyperbilirubinemia in a Patient Receiving Alectinib for Anaplastic Lymphoma Kinase Positive Non-Small-Cell Lung Cancer: A Histological Features
Qian Zhang, Lei Yan, Yujie Bao, Xiaoling Yuan, Donglin Yin, Jie Xu · 2024
Read Hyperbilirubinemia in a Patient Receiving Alectinib for Anaplastic Lymphoma Kinase Positive Non-Small-Cell Lung Cancer: A Histological Features by Qian Zhang, Lei Yan, Yujie Bao, Xiaoling Yuan, Donglin Yin, Jie Xu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11646391.txt.
Description
Zhang and coauthors report liver harm from a lung cancer drug with tissue proof. The drug is a second-wave targeted drug for a gene-linked lung cancer. Liver harm is its most common side effect. No tissue report on yellow bile buildup from it existed.
The patient also had chronic hepatitis B virus infection. After three years on the drug, bile pigment rose to a grave grade. The drug was stopped at once when that occurred. A liver support system then lowered blood pigment levels. Biopsy showed spotty cell death and bile stasis in tissue. Fat in cells and bile plugs were also seen.
Catalog record
| CREATOR | Qian Zhang, Lei Yan, Yujie Bao, Xiaoling Yuan, Donglin Yin, Jie Xu |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 14 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |